Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 30;24(1):384.
doi: 10.1186/s12886-024-03648-7.

Ab-Externo XEN Gel stent implantation effectively treated refractory glaucoma with prior failed shunt tube

Affiliations

Ab-Externo XEN Gel stent implantation effectively treated refractory glaucoma with prior failed shunt tube

Anny M S Cheng et al. BMC Ophthalmol. .

Abstract

Purpose: To assess the efficacy of a gelatin stent (XEN 45 Gel Stent; Allergan) implant in advanced glaucoma eyes that have failed prior aqueous shunt implantation.

Methods: We retrospectively reviewed 6 patients with refractory glaucoma, defined as persistently high IOP (> 21 mmHg) despite taking at least 3 IOP-lowering medications subsequent to undergoing a glaucoma drainage device (GDD) with or without a second GDD or cilioablative procedure. Eyes with previous failed GDD underwent subconjunctival 0.3 cc (0.4 mg/ml) mitomycin C, tenonectomy, and placement of an ab- externo XEN stent. The outcome measures included change in IOP and the number of glaucoma medications. Success was defined as patients achieving an IOP ≤ 18 mmHg with a percentage reduction of 25% or 15 mmHg and 40% mean IOP reduction from baseline while taking the same number or fewer medications.

Results: All six eyes with age of 77.6 ± 7.82 years who underwent XEN implantation following previous GDD surgery had primary open-angle glaucoma. The IOP decreased significantly from 32.33 ± 5.99 to 12.67 ± 3.27 mmHg (p < 0.001) with a follow-up of 13.9 ± 2 (11.7-16.7) months. Visual acuity and visual field remained stable after XEN placement. Compared to the baseline number of medications of 4.2 ± 0.8, all medication was discontinued except in one eye on two drops at the end of the follow-up. The overall surgical success rate was 100%. No complications, needling, or additional procedures were required.

Conclusion: This study described successful implantation of the XEN stent following failed GDD. XEN Gel stent implantation associated with mitomycin C and tenonectomy can be considered a viable surgical option for patients with a history of previously failed tube shunt requiring further IOP lowering.

Keywords: Glaucoma drainage device; Minimally invasive Glaucoma surgeries; Shunt tube; Tenonectomy; XEN Gel Stent.

PubMed Disclaimer

Conflict of interest statement

None of the authors have conflicts of interest.

Figures

Fig. 1
Fig. 1
Functional bleb of XEN Stent. An elevated subconjunctival bleb is drained by a XEN stent located in the superonasal quadrant

References

    1. Bourne RRA, Taylor HR, Flaxman SR, et al. Number of People Blind or visually impaired by Glaucoma Worldwide and in World regions 1990–2010: a Meta-analysis. PLoS ONE. 2016;11:e0162229. 10.1371/journal.pone.0162229. 10.1371/journal.pone.0162229 - DOI - PMC - PubMed
    1. Coleman AL, Kodjebacheva G. Risk factors for glaucoma needing more attention. Open Ophthalmol J. 2009;3:38–42. 10.2174/1874364100903020038. 10.2174/1874364100903020038 - DOI - PMC - PubMed
    1. Gedde SJ, Herndon LW, Brandt JD, et al. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153:804–e8141. 10.1016/j.ajo.2011.10.024. 10.1016/j.ajo.2011.10.024 - DOI - PMC - PubMed
    1. Sidoti PA, Baerveldt G. Glaucoma drainage implants. Curr Opin Ophthalmol. 1994;5:85–98. 10.1097/00055735-199404000-00013. 10.1097/00055735-199404000-00013 - DOI - PubMed
    1. Agrawal P, Bhardwaj P. Glaucoma drainage implants. Int J Ophthalmol. 2020;13:1318–28. 10.18240/ijo.2020.08.20. 10.18240/ijo.2020.08.20 - DOI - PMC - PubMed

LinkOut - more resources